Apixaban cohort Dabigatran cohort Apixaban cohort Rivaroxaban cohort Dabigatran cohort Rivaroxaban cohort
N/Mean %/SD N/Mean %/SD STD* N/Mean %/SD N/Mean %/SD STD* N/Mean %/SD N/Mean %/SD STD*
Sample size 6884 100% 6884 100% 0 20,431 100% 20,431 100% 0 7103 100% 7103 100% 0
Age 70.5 10.0 70.0 9.75 4.23 71.5 9.8 71.5 9.7 0.85 69.7 10.0 69.5 9.9 1.40
Gender
Male 3776 54.9% 3810 55.3% 0.99 10,596 51.9% 10,614 52.0% 0.18 3982 56.1% 4171 58.7% 5.38
US geographic region
Northeast 1256 18.2% 1255 18.2% 0.04 3339 16.3% 3356 16.4% 0.22 1345 18.9% 1445 20.3% 3.54
Midwest 1624 23.6% 1640 23.8% 0.55 4850 23.7% 4861 23.8% 0.13 1688 23.8% 1613 22.7% 2.50
South 2966 43.1% 2962 43.0% 0.12 9563 46.8% 9580 46.9% 0.17 2999 42.2% 2920 41.1% 2.26
West 1008 14.6% 1000 14.5% 0.33 2606 12.8% 2561 12.5% 0.66 1038 14.6% 1098 15.5% 2.36
Other 30 0.4% 27 0.4% 0.68 73 0.4% 73 0.4% 0.00 33 0.5% 27 0.4% 1.30
Race (only for Humana
and Medicare)
White 4361 88.2% 4358 88.1% 0.19 13,910 89.2% 13,926 89.3% 0.33 4368 88.1% 4374 88.2% 0.37
Black 321 6.5% 322 6.5% 0.08 994 6.4% 1001 6.4% 0.18 325 6.6% 318 6.4% 0.57
Other 265 5.4% 267 5.4% 0.18 692 4.4% 669 4.3% 0.72 266 5.4% 267 5.4% 0.09
1|2|3|4|5|6|7|8